INFINIUM Stock Overview
Engages in the manufacturing and supplying of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Infinium Pharmachem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹191.75 |
| 52 Week High | ₹315.70 |
| 52 Week Low | ₹178.05 |
| Beta | 0 |
| 11 Month Change | -13.99% |
| 3 Month Change | -15.15% |
| 1 Year Change | -21.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 159.47% |
Recent News & Updates
Many Still Looking Away From Infinium Pharmachem Limited (NSE:INFINIUM)
Aug 04
Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Jun 12Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Nov 06Shareholder Returns
| INFINIUM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.2% | 2.9% | 3.4% |
| 1Y | -21.3% | 54.2% | 44.3% |
Return vs Industry: INFINIUM underperformed the Indian Pharmaceuticals industry which returned 54.2% over the past year.
Return vs Market: INFINIUM underperformed the Indian Market which returned 44.3% over the past year.
Price Volatility
| INFINIUM volatility | |
|---|---|
| INFINIUM Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: INFINIUM has not had significant price volatility in the past 3 months.
Volatility Over Time: INFINIUM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 130 | Sanjaykumar Patel | www.infiniumpharmachem.com |
Infinium Pharmachem Limited engages in the manufacturing and supplying of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. The company provides iodine derivatives and iodine based molecules / APIs / Iodination reaction based bulk drugs. It also provides potassium iodide and iodate, sodium iodide, iodine, povidone, and iodoform products.
Infinium Pharmachem Limited Fundamentals Summary
| INFINIUM fundamental statistics | |
|---|---|
| Market cap | ₹2.67b |
| Earnings (TTM) | ₹113.02m |
| Revenue (TTM) | ₹1.36b |
23.6x
P/E Ratio2.0x
P/S RatioIs INFINIUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INFINIUM income statement (TTM) | |
|---|---|
| Revenue | ₹1.36b |
| Cost of Revenue | ₹1.03b |
| Gross Profit | ₹325.55m |
| Other Expenses | ₹212.53m |
| Earnings | ₹113.02m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.12 |
| Gross Margin | 24.00% |
| Net Profit Margin | 8.33% |
| Debt/Equity Ratio | 18.7% |
How did INFINIUM perform over the long term?
See historical performance and comparison